PSMC4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1478606	0.58	12/20
SCHEMBL607010	0.56	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1477637	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20
SCHEMBL609278	0.54	11/20
SCHEMBL607553	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL606932	0.53	11/20
SCHEMBL1477893	0.53	11/20
SCHEMBL608362	0.53	11/20
SCHEMBL608599	0.53	11/20
SCHEMBL1327441	0.53	11/20
SCHEMBL605129	0.52	11/20
SCHEMBL608009	0.52	11/20
SCHEMBL1478157	0.52	11/20
SCHEMBL609081	0.52	11/20
SCHEMBL606926	0.52	11/20

Clinical trials — most relevant to PSMC4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy	PHASE2	COMPLETED
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	PHASE2	RECRUITING
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer	PHASE2	COMPLETED
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck	PHASE2	COMPLETED
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
The Pathophysiology of Bortezomib Induced Peripheral Neuropathy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PSMC4 binder may also engage these)

Protein	Name	Similarity
Q63570	—	1.000	Q63570 →
Q3T030	—	1.000	Q3T030 →
Q4R7L3	—	1.000	Q4R7L3 →
P54775	—	1.000	P54775 →
P54778	—	1.000	P54778 →
P46507	—	1.000	P46507 →
Q9SEI4	—	1.000	Q9SEI4 →
P46471	—	1.000	P46471 →
Q63347	—	1.000	Q63347 →
PSMC2	26S proteasome regulatory subunit 7	0.999	landscape →
Q4R4R0	—	0.999	Q4R4R0 →
Q01939	—	0.999	Q01939 →
Q8SRH0	—	0.998	Q8SRH0 →
P53549	—	0.998	P53549 →
Q54PN7	—	0.997	Q54PN7 →
O42931	—	0.997	O42931 →
P54776	—	0.997	P54776 →
Q5R8D7	—	0.997	Q5R8D7 →
O42586	—	0.997	O42586 →
Q8SQK0	—	0.996	Q8SQK0 →
Q2KIW6	—	0.996	Q2KIW6 →
PSMC6	26S proteasome regulatory subunit 10B	0.996	landscape →
P62334	—	0.996	P62334 →
O04019	—	0.996	O04019 →
P78578	—	0.996	P78578 →
O88685	—	0.996	O88685 →
Q8SR13	—	0.996	Q8SR13 →
Q5E9F9	—	0.996	Q5E9F9 →
O74894	—	0.996	O74894 →
P46472	—	0.996	P46472 →